Artiva (ARTV) Director Elizabeth Hougen Receives 16,250-Share Award

What Happened
Elizabeth L. Hougen, a director of Artiva Biotherapeutics (ARTV), received an award on 2026-09-10 covering 16,250 shares. The filing reports the acquisition as a derivative award at $0.00 (no cash paid at grant). This is a grant of an option/award — not an open-market purchase or sale.

Key Details

• Transaction date: 2026-09-10; Form 4 filed: 2026-09-14 (filed within the required reporting window).
• Transaction type/code: Award/Grant (A); reported price per share: $0.00; amount: 16,250 shares (derivative).
• Shares owned after transaction: not disclosed in the provided filing.
• Footnote: The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the issuer's 2027 annual stockholder meeting.
• No indication of a 10b5-1 plan, cashless exercise, tax withholding, or late filing in the provided details.

Context
This was a compensation award (option/award) to a director that vests over time; it does not represent an immediate market purchase or sale. Such grants are common as part of director compensation and do not, by themselves, indicate a change in a director's current trading stance.